Annexin Pharmaceuticals AB
The answer first
Does Annexin Pharmaceuticals beat the market?
No, Annexin Pharmaceuticals has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 22% of Nordic stocks
- Quality99
- Value4
- Trend6
No. 126 of 195 in healthcare
Max for seven days
Follow Annexin Pharmaceuticals with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Annexin Pharmaceuticals
Your first answer is free, no account needed.
Do you own Annexin Pharmaceuticals, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Annexin Pharmaceuticals and a few more. Free, no card.
Super Stock+46.4%In short
- Annexin Pharmaceuticals has fallen 65.3% over the past year, including dividends.
- Overall, Annexin Pharmaceuticals ranks better than 22% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 92.5%. The price is 97.6% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 22% of Nordic stocks.
No. 126 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 7 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−341.2%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 169 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity5.2
- P/SPrice divided by sales–
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 167 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−34.2%
- 6 months−33.5%
- 9 months−55.5%
- 12 months−65.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Annexin Pharmaceuticals
Annexin Pharmaceuticals AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.


See the full analysis of Annexin Pharmaceuticals.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card